Profilaktyka nagłego zgonu sercowego – rola wszczepialnego kardiowertera-defibrylatora

• Authors: Artur Klimczak , Marcin Rosiak , Michał Chudzik

Title variants

EN

Prevention of sudden cardiac death – the role of automatic implantable cardioverter-defibrillator

• Languages of publication: PL

Abstracts

PL

Nagły zgon sercowy (NZS) to zgon w ciągu pierwszej godziny od wystąpienia objawów. Najczęstszą przyczyną NZS są groźne komorowe zaburzenia rytmu serca. Chorzy z dysfunkcją skurczową lewej komory serca to pacjenci szczególnie zagrożeni wystąpieniem NZS. Najważniejszą metodą prewencji NZS jest terapia polegająca na wszczepieniu kardiowerteradefibrylatora (ang. implantable cardioverter-defibrillator – ICD). Działanie ICD polega na rozpoznaniu groźnej arytmii komorowej serca i przeprowadzeniu odpowiedniej terapii elektrycznej (stymulacja antyarytmiczna, bądź też wyładowania wysokoenergetyczne). Implantacja ICD może zostać wykonana u pacjentów, u których doszło w przeszłości do nagłego zatrzymania krążenia w mechanizmie częstoskurczu komorowego lub migotania komór (w ramach tzw. prewencji wtórnej) lub u pacjentów, którzy obarczeni są większym ryzykiem NZS w przyszłości (w ramach tzw. prewencji pierwotnej). Praca omawia zasady działania ICD oraz prezentuje aktualne wskazania do terapii ICD, zarówno w prewencji pierwotnej, jak i wtórnej.

EN

Sudden cardiac death is a significant problem in cardiac patients. The modern invasive cardiology offers important tool in fight against ventricular rhythm disturbances, which are the most frequent cause of sudden cardiac death. Automatic cardioverter-defibrillator through electric therapy (antyarrhythmia stimulation or high energy shock) interrupts the episode of life-threating ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) and therefore it protect patient from sudden cardiac death. Implantation of ICD may be performed in patients, who had the episode of ventricular tachycardia or ventricular fibrillation in the past already (within the secondary prevention of sudden cardiac death) and also in patients, which didn’t have the episode of ventricular tachycardia or ventricular fibrillation in the past but they have higher risk of sudden cardiac death in the future (within primary prevention of sudden cardiac death).

Keywords

EN

ICD; arytmia; cardioverter-defibrillator; kardiowerter-defibrylator; nagły zgon sercowy; sudden cardiac death; ventricular arrhythmia

Discipline

• MEDICINE: MEDICINE

• Publisher: Łódzkie Towarzystwo Naukowe
• Journal: Folia Medica Lodziensia
• Year: 2010
• Volume: 37
• Issue: 2
• Pages: 227-242

Contributors

author

Artur Klimczak

• Zakład Elektrokardiologii, Uniwersytecki Szpital Kliniczny im. WAM-CSW, Łódź, Sterlinga 1/3,

author

Marcin Rosiak

• Klinika Kardiologii, I Katedra Kardiologii i Kardiochirurgii, Uniwersytet Medyczny w Łodzi

author

Michał Chudzik

• Zakład Elektrokardiologii, Uniwersytecki Szpital Kliniczny im. WAM-CSW, Łódź, Sterlinga 1/3,

References

• Buxton AE, Marchlinski FE, Waxman HL, Flores BT, Cassidy DM, Josephson ME. Prognostic factors in non-sustained ventricular tachycardia. Am J Cardiol. 1984; 53:1275–1279.
• Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. The Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999; 341:1882–1890.
• Kadish A, Dyer A, Daubert JP, Quigg R, Estes M, Kelley P i wsp. Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. N Engl J Med. 2004; 350:2151-2158.
• Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989; 80:1675 1680.
• Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989; 117:151-159.
• Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984; 69:250–258.
• Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH i wsp. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781–788.
• Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H i wsp. Risk Stratification for Primary Implantation of a Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol. 2008; 51:288-296.
• Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997; 350: 1417-1424.
• Buxton AE, Sweeney MO, Wathen MS, Josephson ME, Otterness MF, Hogan-Miller E i wsp. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators. J Am Coll Cardiol. 2005; 46:310–316.
• Dhar R, Alsheikh-Ali AA, Estes NA III, Moss AJ, Zareba W, Daubert JP i wsp. Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart Rhythm. 2008; 5:807–813.
• MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). The Lancet. 1999; 9169:2001-2007.
• Myerburg RJ, Mitrani R, Interian A, Castellanos A: Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impast. Circulation. 1998; 97:1514-1521.
• Böcker D, Br Heart J, Isbruch F, Fastenrath C, Castrucci M, Hammel D i wsp. Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J. 1995; 73:158-163.
• Gold MR: The implantable cardioverter defibrillator. W: Ellenbogen KA, Wood MA, Cardiac Pacing and ICDs. Blackwell Publishing Inc. 2005.
• Zareba W, Moss AJ, Hall WJ, Wilber DJ, Ruskin JN, McNitt S i wsp. Clinical course and implantable cardioverter defibrillator therapy in postinfarctionwomen with severe left ventricular dysfunction for the MADIT II Investigators. J Cardiovasc Electrophysiol. 2005; 16:1265–1270.
• Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML i wsp. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Card. 2004; 43:1459–1465.
• Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R I wsp. Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction. N Engl J Med. 2004; 351: 2481-2488.
• Moss AJ, Zeremba W, Hall J, Klein H, Wilber DJ, Cannom DS i wsp. Prophylactic implantation of a defibrillator in patients with Myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346:877-883.
• Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H i wsp. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335:1933-1940.
• McAnulty J, Halperin B, Kron J, Larsen G, Raitt M, Swenson R i wsp. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med. 1997; 337:1576-1583.
• Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ i wsp. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000; 101:1297-1302.
• Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G i wsp. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. N Engl J Med. 2005; 352:2581-2588.
• Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R i wsp. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005; 352:225–237.
• Ruskin JN, McGovern B, Garan H, DiMarco JP, Kelly E. Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med. 1983; 309:1302 1306.
• Bigger JT, for The Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac Defibrillators in patients at high risk for ventricular arrhythmias after Coronary Artery Bypass Graft Surgery. N Engl J Med. 1997; 337:1569-1575
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2008; 29:2388-2442.

• Document Type: paper